Intravitreal injections of triamcinolone acetonide for severe vitritis in patients with incomplete Behcet's disease.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 15488806.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To report our experience with intravitreal triamcinolone acetonide (IVTA) injections for the treatment of sight-threatening vitritis. Interventional case series. Three patients with acute severe exacerbations of noninfectious panuveitis and vitritis were treated with IVTA injections alone or as an adjunct to systemic immunosuppressive agents. Rapid clearance of the vitreous inflammation with improvement in visual acuity was observed 1 to 2 weeks after injection. The effect lasted 2 to 6 months, with the shortest duration in the vitrectomized eye of Patient 1. Repeated injections were required in all patients. Intravitreal triamcinolone acetonide may be beneficial in selected cases of vitritis. This treatment modality has a rapid effect and may lower the use of systemic agents.
Medical subject headings
- Behcet Syndrome
- Eye Diseases
- Glucocorticoids
- Triamcinolone Acetonide
- Vitreous Body